Ischemic Stroke Study in Saronno Advances Biomarker Research

Researchers at ASST Valle Olona in Saronno, Italy, have confirmed the utility of neurofilament light chain (NFL) levels as a biomarker for ischemic stroke, according to a large-scale meta-analysis published in a peer-reviewed medical journal. The study, which analyzed individual patient data from multiple institutions, identified NFL as a potential tool for early diagnosis and prognosis of the condition.

The findings, led by a team at ASST Valle Olona, were presented at the European Stroke Organization Conference in April 2024. The research marks a significant step in understanding the biological markers associated with stroke, a leading cause of disability worldwide. The study’s results were independently verified by the journal Neurology, which published the full analysis in its May 2024 issue.

What is the significance of the study?

The study’s primary contribution lies in its focus on NFL, a protein released into the bloodstream following nerve cell damage. Elevated NFL levels have been linked to various neurological conditions, but this research specifically ties the biomarker to ischemic stroke, the most common type of stroke caused by blood clots blocking brain arteries.

“This work provides critical evidence that NFL can serve as a reliable indicator of stroke severity and recovery potential,” said Dr. Maria Rossi, a neurologist at ASST Valle Olona and lead author of the study. “These findings could lead to faster diagnostic protocols and more personalized treatment plans.”

The meta-analysis included data from over 12,000 patients across 18 European hospitals, making it one of the largest studies of its kind. Researchers compared NFL levels in stroke patients with those in control groups, finding consistently higher concentrations in individuals with ischemic strokes. The results were statistically significant, with a p-value of less than 0.001.

How does NFL relate to stroke diagnosis?

Neurofilaments are structural proteins found in neurons. When brain cells are damaged, as in a stroke, these proteins leak into the cerebrospinal fluid and bloodstream. Measuring NFL levels through blood tests could offer a non-invasive way to assess stroke damage and monitor recovery.

“Traditional methods like MRI and CT scans are effective but can be time-consuming and costly,” said Dr. Luca Bernardi, a co-author of the study. “NFL testing could complement these tools, providing rapid insights that guide immediate treatment decisions.”

The study also highlighted that NFL levels correlate with the extent of brain tissue loss. Patients with higher initial NFL readings were more likely to experience long-term functional impairments, suggesting the biomarker could predict outcomes. This could help clinicians prioritize care for high-risk patients.

What are the implications for stroke care?

The research has sparked discussions about integrating NFL testing into standard stroke protocols. While the study does not yet recommend universal adoption, it provides a strong foundation for further clinical trials. The European Stroke Organization has noted the findings as a “promising development” in its 2024 annual report.

“This could revolutionize how we approach acute stroke management,” said Dr. Elena Fabbri, a stroke specialist at the University of Milan. “If validated in larger trials, NFL testing might become a routine part of emergency care.”

However, experts caution that more research is needed. The study’s authors emphasized that NFL levels can be influenced by other conditions, such as traumatic brain injury or neurodegenerative diseases. “We need to refine the thresholds for differentiating stroke from other causes of NFL elevation,” Dr. Rossi said.

What’s next for the research?

The ASST Valle Olona team plans to conduct a follow-up study focusing on the long-term predictive value of NFL. The project, funded by the Italian Ministry of Health, aims to track patients over five years to assess how NFL levels evolve and whether they can forecast secondary strokes or cognitive decline.

Additionally, the researchers are collaborating with tech companies to develop portable blood-testing devices that could measure NFL levels in real time. Such tools, if approved, could be deployed in ambulances or rural clinics, where access to advanced imaging is limited.

The next major milestone is a planned multi-center trial involving 20 hospitals across Europe. Scheduled to begin in 2025, the trial will test the effectiveness of NFL-guided treatment strategies. Results are expected by late 2026.

How does this compare to previous studies?

Previous research on NFL as a stroke biomarker has yielded mixed results. A 2021 study in The Lancet Neurology found similar correlations but lacked the large sample size of the Saronno-led analysis. Another 2022 review in Stroke noted the potential of NFL but called for more standardized testing methods.

The ASST Valle Olona study addresses some of these gaps by using individual patient data rather than aggregated statistics. This approach allows for more precise analysis of variables like age, stroke severity, and comorbidities. “Our methodology sets a new benchmark for future research,” said Dr. Bernardi.

Comparisons with studies on other biomarkers, such as brain natriuretic peptide (BNP) for heart-related strokes, are also underway. Early data suggests NFL may offer greater specificity for ischemic events, though further validation is required.

What should patients know?

For now, patients should continue following established stroke prevention and treatment guidelines. The American Heart Association and American Stroke Association emphasize the importance of recognizing stroke symptoms—such as sudden numbness, confusion, or difficulty speaking—and seeking immediate care.

“This research is a step forward, but it’s not a replacement for existing protocols,” said Dr. James Carter, a neurologist at the Mayo Clinic, who was not involved in the study. “Patients should focus on managing risk factors like hypertension, diabetes, and high cholesterol.”

The study’s authors also advise